Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26378748 | 1.00 | NEK2 (0.38) | NEK2USP2CYP1A2CRBNCTSK | |
| SCHEMBL25051614 | 1.00 | NEK2 (0.38) | NEK2USP2CYP1A2CRBNCTSK | |
| SCHEMBL24535256 | 0.77 | USP2 (0.33) | NEK2USP2CYP1A2TSHRCYP2C9 | |
| SCHEMBL25051820 | 0.77 | TOP2A (0.33) | — | |
| SCHEMBL15721209 | 0.75 | NEK2 (0.52) | NEK2CRBNCTSK | |
| SCHEMBL24535836 | 0.75 | MGLL (0.39) | USP2 | |
| SCHEMBL12699763 | 0.73 | CYP11B1 (0.44) | NEK2CRBNCYP11B1CYP11B2 | |
| SCHEMBL29257295 | 0.73 | DDB1 (0.33) | CYP1A2CRBNTSHRCYP2D6 | |
| SCHEMBL19946508 | 0.71 | — | — | |
| SCHEMBL1401020 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023018810-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2023-02-16 | — | — | WO | disclosed |